Regenxbio, Duchenne muscular dystrophy and gene therapy
Regenxbio Share Surge 20% on Duchenne Muscular Dystrophy Treatment Trial Data, Expansion
Regenxbio shares surged 20% after disclosing new, positive efficacy and safety data of its Duchenne muscular dystrophy treatment. Shares were recently trading around $11.55. The stock is down 46% on the year.
Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price ...
Regenxbio’s investigational gene therapy improved muscle function for patients with Duchenne muscular dystrophy (DMD) in a phase 1/2 study. | Regenxbio’s investigational gene therapy improved muscle ...
Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.
REGENXBIO Inc. (Nasdaq: RGNX) today announced that AFFINITY DUCHENNE®, the multi-center, open-label trial of RGX-202, a ...
12d
Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on RegenXBio (RGNX – Research Report) and increased the price target to ...
REGENXBIO stock is trading higher on Monday after the company reached a critical point in its trial for Duchenne gene therapy.
With a diverse pipeline targeting high-value indications such as Duchenne muscular dystrophy (DMD) and wet age-related macular degeneration (wet AMD (NASDAQ:AMD)), REGENXBIO has positioned itself as ...
RGX 202 is positioned as a potential best-in-class gene therapy for Duchenne, with promising clinical data and a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback